Axial Biotherapeutics to Participate in 5th Annual BMO Private Company Showcase

WALTHAM, Mass.–(BUSINESS WIRE)–Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5^th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.

Contacts

Investors:
Julie Seidel

Stern Investor Relations, Inc.

212-362-1200

[email protected]